Plitidepsin:机制和临床资料的承诺对COVID-19抗病毒剂。

文章的细节

引用
复制到剪贴板

Papapanou M, Papoutsi E, Giannakas T, Katsaounou P

Plitidepsin:机制和临床资料的承诺对COVID-19抗病毒剂。

J珀耳斯。2021年7月16日,11 (7)。pii: jpm11070668。doi: 10.3390 / jpm11070668。

PubMed ID
34357135 (在PubMed
]
文摘

目前的标准治疗COVID-19缺乏有效的抗病毒药物的选择。Plitidepsin,循环depsipeptide授权为难治性多发性骨髓瘤患者在澳大利亚,最近成为候选人anti-SARS-CoV-2代理人。本综述的目的是总结当前plitidepsin知识的临床资料、抗肿瘤和anti-SARS-CoV-2机制和关联这可用的或预期,临床前或临床证据COVID-19治疗药物的潜力。PubMed,斯高帕斯,中央、clinicaltrials.gov medRxiv和bioRxiv数据库搜索。Plitidepsinexerts its anti-tumour and antiviral properties primarily through acting on isoforms of the host cell's eukaryotic-translation-elongation-factor-1-alpha (eEF1A). Through inhibiting eEF1A and therefore translation of necessary viral proteins, it behaves as a "host-directed" anti-SARS-CoV-2 agent. In respect to its potent anti-SARS-CoV-2 properties, the drug has demonstrated superior ex vivo efficacy compared to other host-directed agents and remdesivir, and it might retain its antiviral effect against the more transmittable B.1.1.7 variant. Its well-studied safety profile, also in combination with dexamethasone, may accelerate its repurposing chances for COVID-19 treatment. Preliminary findings in hospitalized COVID-19 patients, have suggested potential safety and efficacy of plitidepsin, in terms of viral load reduction and clinical resolution. However, the still incomplete understanding of its exact integration into host cell-SARS-CoV-2 interactions, its intravenous administration exclusively purposing it for hospital settings the and precocity of clinical data are currently considered its chief deficits. A phase III trial is being planned to compare the plitidepsin-dexamethasone regimen to the current standard of care only in moderately affected hospitalized patients. Despite plitidepsin's preclinical efficacy, current clinical evidence is inadequate for its registration in COVID-19 patients.Therefore, multicentre trials on the drug's efficacy, potentially also studying populations of emerging SARS-CoV-2 lineages, are warranted.

beplay体育安全吗DrugBank数据引用了这篇文章

药物
药物靶点
药物 目标 类 生物 药理作用 行动
Plitidepsin 延长因子1α2 蛋白质 人类
未知的
 不可用 细节